The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Jan. 08, 2015
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Genoveffa Franchini, Washington, DC (US);

Rafick-Pierre Sekaly, Port Saint Lucie, FL (US);

Slim Fourati, Cleveland, OH (US);

Mark Cameron, Shaker Heights, OH (US);

Monica Vaccari, Washington, DC (US);

Luca Schifanella, Bethesda, MD (US);

Shari Gordon, Research Triangle Park, NC (US);

Melvin Doster, Beltsville, MD (US);

Namal Malimbada Liyanage, Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 14/47 (2006.01); C12N 15/85 (2006.01); A61K 9/127 (2006.01); A61K 38/17 (2006.01); A61K 39/21 (2006.01); G01N 33/569 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); C12Q 1/70 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); A61K 45/06 (2013.01); C12Q 1/702 (2013.01); C12Q 1/703 (2013.01); G01N 33/56988 (2013.01); G01N 33/6887 (2013.01); G01N 33/6893 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/70 (2013.01); C12N 2710/24042 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16234 (2013.01); C12Q 2600/106 (2013.01); G01N 2333/91102 (2013.01); G01N 2333/91205 (2013.01); G01N 2800/52 (2013.01);
Abstract

Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.


Find Patent Forward Citations

Loading…